(Dexamethasone transdermal(Teikoku Pharma USA, Inc.)) - 药物靶点：GR_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Dexamethasone transdermal

靶点

GR

作用机制

GR激动剂(糖皮质激素受体激动剂)

治疗领域

其他疾病

在研适应症-

非在研适应症

肌腱损伤

原研机构

Teikoku Pharma USA, Inc.

在研机构-

非在研机构

Teikoku Pharma USA, Inc.

最高研发阶段终止临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

结构

分子式C22H29FO5

InChIKeyUREBDLICKHMUKA-CXSFZGCWSA-N

CAS号50-02-2

关联

6

项与 Dexamethasone transdermal(Teikoku Pharma USA, Inc.) 相关的临床试验

NCT04538820 / Recruiting临床4期IIT

Dexamethasone Dose for Postoperative Nausea and Vomiting Prophylaxis in Obese Patients

compare the effectiveness of different doses of dexamethasone used for postoperative nausea and vomiting prophylaxis in obese patients and in normal weight patients.

开始日期2021-03-01

申办/合作机构

Diskapi Teaching and Research Hospital

NCT03871829 / Terminated临床2期

A Phase 2 Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination With Carfilzomib and Dexamethasone (DKd) Compared With Carfilzomib and Dexamethasone (Kd) in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab to Evaluate Daratumumab Retreatment

The purpose of this study is to compare the efficacy (rate of very good partial response [VGPR] or better as best response as defined by the International Myeloma Working Group [IMWG] criteria) of daratumumab subcutaneous (Dara-SC) in combination with carfilzomib and dexamethasone (Kd) with the efficacy of Kd in participants with relapsed refractory multiple myeloma who were previously exposed to daratumumab to evaluate daratumumab retreatment.

开始日期2019-05-31

申办/合作机构

Janssen Research & Development LLC

NCT01666210 / Completed临床2期

A Prospective, Multicenter, Randomized, Parallel-Arm, Double-Masked, Vehicle Controlled Phase II Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocular Inflammation and Pain After Cataract Surgery

To evaluate the safety and efficacy of OTX-DP as a sustained release drug (dexamethasone) depot when placed in the canaliculus of the eyelid for the treatment of ocular inflammation and pain in subjects who have undergone cataract extraction with intra-ocular lens implantation.

开始日期2012-10-31

申办/合作机构

Ocular Therapeutix, Inc.

100 项与 Dexamethasone transdermal(Teikoku Pharma USA, Inc.) 相关的临床结果

登录后查看更多信息

100 项与 Dexamethasone transdermal(Teikoku Pharma USA, Inc.) 相关的转化医学

登录后查看更多信息

100 项与 Dexamethasone transdermal(Teikoku Pharma USA, Inc.) 相关的专利（医药）

登录后查看更多信息

100 项与 Dexamethasone transdermal(Teikoku Pharma USA, Inc.) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB01234

研发状态

适应症	最高研发状态	国家/地区	公司
肌腱损伤	终止	-	Teikoku Pharma USA, Inc. 更多

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03871829 (CTgov)	临床2期	多发性骨髓瘤	88	Carfilzomib 70 mg/m^2+Dexamethasone 40 mg+Dexamethasone 20 mg (Arm A: Carfilzomib+Dexamethasone (Kd))	(網夢襯廠遞繭夢網齋鬱) = 壓觸簾選鏇選獵簾膚繭廠醖遞網積壓選願築鹹 (簾範獵遞顧製餘廠襯糧, 鹽簾鏇鹽艱齋鬱襯遞憲 ~ 鑰襯衊窪餘蓋遞淵憲製) 更多	-	2023-12-19
				Carfilzomib 70 mg/m^2+Dexamethasone 40 mg+Dara-SC 1800 mg+Dexamethasone 20 mg (Arm B: Dara-SC in Combination With Kd (DKd))	(網夢襯廠遞繭夢網齋鬱) = 選願遞願鹹觸醖糧壓範廠醖遞網積壓選願築鹹 (簾範獵遞顧製餘廠襯糧, 鹽鏇餘網觸顧蓋顧鑰鏇 ~ 淵醖簾鹽鑰衊網構築簾) 更多
NCT00639002 (CTgov)	临床2期	浆细胞骨髓瘤难治 \| 复发性多发性骨髓瘤	13	Dexamethasone 40 mg+Ruxolitinib 25 mg	蓋艱構範築蓋鏇糧糧網(鏇壓醖醖夢積鏇夢膚鑰) = 衊選願艱獵糧製範選壓艱顧壓範淵膚構積範淵 (範衊夢鑰鏇鏇鑰鬱獵範, 壓顧窪鹹選窪範鏇積簾 ~ 鑰壓夢夢製繭廠醖築蓋)	-	2012-01-23
NCT01605942 (CTgov)	临床1期	白内障 \| 术后炎症 \| 疼痛	8	Dexamethasone Drug Delivery System (Dexamethasone Drug Delivery System)	醖鹹選蓋範範窪鏇衊憲(遞鑰願淵鑰遞膚淵壓艱) = 廠網鏇構壓齋窪構鹽鑰築築淵膚醖築淵齋蓋鹹 (觸築夢簾膚醖鹽衊範衊, 衊網夢鏇糧夢簾鑰網憲 ~ 窪齋觸鑰網醖構蓋獵壓) 更多	-	2015-07-01
				Placebo Drug Delivery System (Placebo Drug Delivery System)	醖鹹選蓋範範窪鏇衊憲(遞鑰願淵鑰遞膚淵壓艱) = 夢齋遞製齋鬱積遞夢鹽築築淵膚醖築淵齋蓋鹹 (觸築夢簾膚醖鹽衊範衊, 廠艱製網糧獵築夢夢觸 ~ 壓簾餘鏇顧獵齋遞鹹艱) 更多
NCT01666210 (CTgov)	临床2期	疼痛 \| 眼部炎症 \| 白内障	60	OTX-DP (Dexamethasone punctum plug) (Dexamethasone Punctum Plug)	窪壓獵襯糧襯範選艱壓(獵齋壓廠窪鏇淵廠鹽積) = 觸築夢選繭鑰積觸範壓憲壓憲壓獵憲艱遞鬱繭 (製壓糧網選窪艱淵繭願, 壓衊願獵簾壓窪築遞築 ~ 築廠顧糧鏇夢窪願鬱築) 更多	-	2017-04-27
				Placebo Vehicle Punctum Plug (Placebo Vehicle Punctum Plug)	窪壓獵襯糧襯範選艱壓(獵齋壓廠窪鏇淵廠鹽積) = 齋蓋襯觸餘壓獵選餘範憲壓憲壓獵憲艱遞鬱繭 (製壓糧網選窪艱淵繭願, 獵鏇齋範簾窪鏇遞鹽蓋 ~ 顧觸憲製範憲齋鑰顧壓) 更多